Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 2—February 2010
Research

Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies1

Anthony T. NewallComments to Author , James G. Wood, Noemie Oudin, and C. Raina MacIntyre
Author affiliations: University of New South Wales, Sydney, New South Wales, Australia (A.T. Newall, J.G. Wood, C.R. MacIntyre); National Institute for Applied Sciences, Lyon, France (N. Oudin)

Main Article

Table 1

Descriptions of 4 pharmaceutical-based pandemic influenza mitigation strategies*

Strategy no. Description
1 Minimum pharmaceutical intervention
2 Antiviral treatment of those clinically infected
3 Population prepandemic vaccination
4 Strategies 2 + 3

*All strategies included an initial antiviral containment effort and distribution of a matched vaccine to the population 180 days after the first locally acquired case.

Main Article

1This material was compiled before the declaration of pandemic (H1N1) 2009 and concerns stockpiling for a future influenza pandemic.

Page created: December 10, 2010
Page updated: December 10, 2010
Page reviewed: December 10, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external